Subscribe To
MED / Medifast, Inc. (MED) CEO Dan Chard on Q2 2022 Results - Earnings Call Transcript
MED News
By Zacks Investment Research
November 2, 2023
Medifast (MED) Queues for Q3 Earnings: What Awaits the Stock?
Medifast's (MED) third-quarter results are likely to reflect concerns surrounding customer acquisition amid a challenging landscape. However, a focus more_horizontal
By Zacks Investment Research
September 11, 2023
Medifast (MED) Gains on OPTAVIA Lifestyle Solution Strength
Medifast's (MED) OPTAVIA program is a robust and adaptable solution focused on health and wellness. This holistic approach positions it for sustained more_horizontal
By Zacks Investment Research
September 6, 2023
Why Is Medifast (MED) Down 7.4% Since Last Earnings Report?
Medifast (MED) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Zacks Investment Research
August 8, 2023
Medifast's (MED) Q2 Earnings Top Estimates, Sales Decline Y/Y
Medifast's (MED) second-quarter 2023 results reflect lower sales and earnings on reduced Coach productivity and cost inflation. more_horizontal
By Zacks Investment Research
August 7, 2023
Medifast (MED) Q2 Earnings and Revenues Surpass Estimates
Medifast (MED) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings more_horizontal
By Seeking Alpha
August 4, 2023
Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Medifast has seen a significant decline in its stock price and market cap in the past 2 years, reflecting investors' pessimism towards the company. Th more_horizontal
By Seeking Alpha
July 21, 2023
In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Medifast, a health and wellness company, has seen its stock price decline by 76% since 2021, despite its Optavia platform helping over 2 million custo more_horizontal
By Seeking Alpha
June 14, 2023
Medifast: A Revamp Is Necessary, An Embrace Of GLP-1s Can Help
I view Medifast's traditional business model at increasing risk from the growing popularity of GLP-1-based drugs. Recent M&A activity within the indus more_horizontal